ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30.
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial.
IDEAYA Biosciences (IDYA) Selects Move-Forward Phase 2 Expansion Dose for IDE397 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Trial will evaluate IDE161, IDEAYA s investigational PARG inhibitor, in combination with KEYTRUDA® , Merck s anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer Potential.
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting.